Moleculin Biotech is trading 14.8% down at $1.86 on heavy early-session weakness, despite no fresh company-specific news being identified so far.
- The decline outpaces the broader biotech sector and cautious overall market tone, suggesting a reaction to existing negative sentiment.
- The move indicates traders may be responding to the stock's high-risk profile rather than a newly disclosed corporate event.